LXRX - Lexicon Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.3200
-0.0900 (-6.38%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.4100
Open1.3800
Bid0.0000 x 1100
Ask0.0000 x 2200
Day's Range1.3200 - 1.4100
52 Week Range1.1300 - 11.8800
Volume538,821
Avg. Volume1,145,879
Market Cap140.279M
Beta (3Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)-0.8390
Earnings DateOct 30, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • GuruFocus.com

    Lexicon Pharmaceuticals Inc (LXRX) President and CEO Lonnel Coats Bought $54,000 of Shares

    President and CEO of Lexicon Pharmaceuticals Inc (30-Year Financial, Insider Trades) Lonnel Coats (insider trades) bought 40,000 shares of LXRX on 08/19/2019 at an average price of $1.35 a share. Continue reading...

  • GlobeNewswire

    Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

    THE WOODLANDS, Texas, Aug. 09, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and.

  • GlobeNewswire

    Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes

    Changes in Clinical Biomarkers Suggestive of Favorable Effects on Kidney Function in Patients with Type 1 Diabetes Results Recently Published in Diabetes Care THE WOODLANDS,.

  • Thomson Reuters StreetEvents

    Edited Transcript of LXRX earnings conference call or presentation 31-Jul-19 12:00pm GMT

    Q2 2019 Lexicon Pharmaceuticals Inc Earnings Call

  • Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
    Zacks

    Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates

    Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.

  • Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
    Zacks

    Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

    Lexicon (LXRX) delivered earnings and revenue surprises of -144.44% and -60.73%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update

    THE WOODLANDS, Texas, July 31, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended.

  • GlobeNewswire

    Lexicon Pharmaceuticals Announces Date Change for Second Quarter 2019 Financial Results Conference Call and Webcast to July 31, 2019

    Lexicon Pharmaceuticals, Inc. (LXRX), announced today that it has changed the date of its previously announced earnings release, conference call and webcast and will now release financial results for the second quarter of 2019 on Wednesday, July 31, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss the financial results and to provide a business update.

  • Why Cooper Tire & Rubber, Insperity, and Lexicon Pharmaceuticals Slumped Today
    Motley Fool

    Why Cooper Tire & Rubber, Insperity, and Lexicon Pharmaceuticals Slumped Today

    Earnings and other woes weighed on these stocks.

  • Here's Why Lexicon Pharmaceuticals Is Collapsing Today
    Motley Fool

    Here's Why Lexicon Pharmaceuticals Is Collapsing Today

    Sanofi is walking away from an important collaboration, leaving shareholders wondering what's next.

  • MarketWatch

    Lexicon's stock loses more than half its value after Sanofi's notice to end alliance

    Shares of Lexicon Pharmaceuticals Inc. lost more than half their value (down 53.4%) toward a record low in active premarket trading Monday, after the drug maker said Sanofi wanted to end the alliance around its diabetes treatment Zynquista. The stock was on track to open 38% below its Jan. 29, 2019 record low close of $4.36, with trading volume of 583,000 shares already more than the full-day average of 349,800 shares. Lexicon said it considers Sanofi's notice to be invalid and "in breach of contract." Sanofi's decision to terminate the alliance late Friday came as Lexicon provided preliminary data from a phase 3 trial of Zynquista; Lexicon said it has not yet received the underlying data and expects to conduct its own review and validation of the statistical analysis. Analyst Stephen Wiley at Stifel Nicolaus downgraded Lexicon's stock to hold from buy and cut his price target to $4 from $10, saying Sanofi's notice creates more uncertainty for Lexicon's story, which "already lacked meaningful visibility." The stock has lost 14% year to date through Friday, while the S&P 500 has gained 21%.

  • Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
    Reuters

    Sanofi ends partnership with Lexicon to develop add-on pill for diabetes

    Sanofi said the termination of the partnership comes after the results of three late-stage studies of the oral drug, Zynquista, which is being jointly developed by the two companies. In a separate statement, Lexicon said it had not yet received the underlying data from the studies and that it expects to conduct its own review. "While we are disappointed in the position taken by Sanofi, we are confident in the strength of the data we have seen thus far in the type 2 diabetes program," Lexicon Chief Executive Officer Lonnel Coats said.

  • Reuters

    UPDATE 1-Sanofi ends partnership with Lexicon to develop add-on pill for diabetes

    French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop a drug for use with insulin in patients with type 1 and type 2 diabetes. Shares of Lexicon fell nearly 40% in extended trading. Sanofi said the termination of the partnership comes after the results of three late-stage studies of the oral drug, Zynquista, which is being jointly developed by the two companies.

  • GlobeNewswire

    Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program

    Lexicon Pharmaceuticals, Inc. (LXRX), received preliminary topline results from Sanofi for three Phase 3 trials of Zynquista™ (sotagliflozin) in adults living with type 2 diabetes from the InSynchrony clinical program. In SOTA-MET, Zynquista 400 mg demonstrated a statistically significant reduction in blood sugar control (A1C) compared to placebo at 26 weeks in patients on metformin. In SOTA-CKD3, Zynquista 400 mg showed a statistically significant reduction in A1C in the entire population of patients with moderate (stage 3) chronic kidney disease (CKD) and in the subpopulation of patients with a glomerular filtration rate of 45-

  • Reuters

    Sanofi ends partnership with Lexicon to develop diabetes drug

    French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop and manufacture a drug for use with insulin in patients with type 1 and type 2 diabetes. Sanofi said the termination of the partnership comes after the results of a late stage study of the drug, sotagliflozin.

  • How Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Can Impact Your Portfolio Volatility
    Simply Wall St.

    How Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Can Impact Your Portfolio Volatility

    Anyone researching Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) might want to consider the historical volatility of the...

  • GlobeNewswire

    Lexicon Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on August 1, 2019

    Lexicon Pharmaceuticals, Inc. (LXRX), will release its second quarter 2019 financial results on Thursday, August 1, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss the financial results and to provide a business update.

  • Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
    Zacks

    Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes
    Zacks

    AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes

    AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.

  • Here is What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX)
    Insider Monkey

    Here is What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX)

    Is Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]

  • Should You Be Pleased About The CEO Pay At Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX)
    Simply Wall St.

    Should You Be Pleased About The CEO Pay At Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX)

    Lonnel Coats has been the CEO of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) since 2014. This analysis aims first to...

  • Markit

    See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

    Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for LXRX with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding LXRX is favorable, with net inflows of $2.55 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire

    Lexicon Pharmaceuticals to Present New Clinical Data at 79th American Diabetes Association Scientific Sessions

    Lexicon Pharmaceuticals, Inc. (LXRX), today announced new analyses of clinical data for sotagliflozin will be presented at the upcoming 79th American Diabetes Association (ADA) Scientific Sessions in San Francisco, California. The five accepted posters reflect Lexicon and its collaborator, Sanofi’s efforts to address the unmet need and potential treatment options for the management of type 1 diabetes.